Counsel Peter Sandel spoke at a panel at the American Conference Institute’s 15th Summit on Biosimilars & Innovator Biologics in New York City on June 21, 2024. The panel, titled “To Dance or Not to Dance? Updated Venue Selection Matrices for a Maturing Biosimilar Industry,” explored the fundamentals of the “patent dance,” a series of legal and regulatory steps designed to handle patent disputes arising from biosimilars. Peter, Steven D. Maslowski, partner at Akin Gump Strauss Hauer & Feld, and Keri L. Shaubert, member of Cozen O’Connor, discussed the factors to consider when choosing between various venues and the concept of irreparable harm, among other topics.
Peter represents pioneering pharmaceutical and biotechnology companies in all states of patent litigation. He has litigated complex patent disputes in a wide array of areas, including biosimilar challenges, DNA sequencing, and novel treatments for life-threatening diseases.